Back to All Combinations

PIK3CA + KRAS

Poor Prognosis
5.00% Prevalence Level 3 PIK3CA Pathway
Genes Involved
PIK3CA KRAS
Treatment Implications

Dual pathway activation = aggressive biology.

Recommended Treatments
Intensive chemotherapy
Clinical trials
Treatments to Avoid
Anti-EGFR
Study References

TCGA

Key Statistics
5.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Consider aspirin for PIK3CA component.
Information

Category: PIK3CA Pathway

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.